When Steadiness meets Sustainability


Pharmaline enters the world of diabetes with its first generic of Sitagliptin on the Lebanese Market.

Diabetes prevalence estimated to 9.3% rising to 10.2% by 2030 is the seventh leading cause of death

A brand of Sitagliptin and Sitagliptin with metformin that belong to the family of DPP4 inhibitors, Sagifor and Sagimet  treat Diabetes type II, by increasing the amounts of insulin that lower blood sugar when it is high.  

Sagifor and Sagimet provide a sustainable Hb1Ac decrease while allowing patient to maintain a stable weight.


Share on